Latest news with #CharlesRiver
Yahoo
3 days ago
- Business
- Yahoo
Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass., June 02, 2025--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit View source version on Contacts Investor Relations Contact:Todd SpencerCorporate Vice President, Investor
Business Wire
3 days ago
- Business
- Business Wire
Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45 th Annual Growth Stock Conference on Tuesday, June 3 rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4 th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit
Yahoo
7 days ago
- Business
- Yahoo
Charles River Laboratories International, Inc. (CRL): A Bull Case Theory
We came across a bullish thesis on Charles River Laboratories International, Inc. (CRL) on scuttleblurb's Substack. In this article, we will summarize the bulls' thesis on CRL. Charles River Laboratories International, Inc. (CRL)'s share was trading at $136.25 as of 28th May. CRL's trailing and forward P/E were 25.07 and 14.41 respectively according to Yahoo Finance. A technician in a lab inspecting an ELISA test kit for use in biopharmaceutical diagnostics. Life sciences companies produce tangible tools like assays, bioreactors, and chromatography columns used across three key drug development phases: preclinical, clinical, and manufacturing. The preclinical phase, often split into discovery and regulatory safety testing, involves identifying and optimizing drug candidates through high-throughput screening and ADME-Tox tests, assessing absorption, distribution, metabolism, excretion, and toxicity. Charles River plays a significant role here by supplying cells and animals for testing, running screenings, and conducting ADME evaluations, although early discovery is mostly handled in-house due to its exploratory nature. As drug candidates progress, testing becomes more regulated, and outsourcing rises, particularly for Safety Assessment, which focuses on toxicity testing using larger mammals under strict Good Laboratory Practices (GLP). Charles River excels at these structured studies, which form about 60% of tox testing and require rigorous documentation and quality assurance. After successful safety testing, drugs enter clinical trials where clinical CROs lead, but Charles River remains involved through its Microbial Solutions and Biologics Testing divisions, ensuring drugs are free from microbial contamination and validating biologics' purity, potency, and safety. Despite initial attempts to enter drug manufacturing (CDMO) through acquisitions, Charles River exited a crowded small molecule space but reentered more strategically with acquisitions in cell and gene therapy manufacturing, aligning better with its biologics testing expertise. This focused approach positions Charles River as a critical and growing player in supporting biopharma through complex preclinical safety testing and manufacturing for cutting-edge therapies. For a comprehensive analysis of another standout stock in the healthcare industry, be sure to check out our article on Danaher Corporation (DHR), wherein we summarized a bullish thesis by Best Anchor Stocks on Substack. Charles River Laboratories International, Inc. (CRL) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 39 hedge fund portfolios held CRL at the end of the first quarter which was 45 in the previous quarter. While we acknowledge the risk and potential of CRL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CRL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Business Insider
28-05-2025
- Business
- Business Insider
Deckers downgraded, Morgan Stanley upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Confident Investing Starts Here: Top 5 Upgrades: Erste Group upgraded Morgan Stanley (MS) to Buy from Hold. The company's earnings in 2025 will increase more strongly than revenue and its return on equity is significantly higher than that competitors, the firm tells investors in a research note. Baird upgraded (WIX) to Outperform from Neutral with a price target of $190, down from $215. The company's product 'is becoming increasingly compelling' and expectations now seem more reasonable post the Q1 report, the firm tells investors in a research note. Northland upgraded SolarEdge (SEDG) to Market Perform from Underperform with an unchanged price target of $15.50. Shares have declined meaningfully since the firm's downgrade on May 16, notes the firm, which argues that regardless of what legislation ultimately looks like, utility-scale solar is 'the cheapest and fastest way to add generation capacity' and SolarEdge is well-positioned as a non-Chinese supplier with cybersecurity capabilities. Redburn Atlantic upgraded Charles River (CRL) to Buy from Neutral with a price target of $182, down from $188. The announcement that activist Elliott is now Charles River's largest investor and the company conducting a 'wide-ranging' strategic offers a potential catalyst for the shares, the firm tells investors in a research note. JPMorgan upgraded WM (WM) to Overweight from Neutral with a price target of $277, up from $225, after transfer in analyst coverage. The firm expects WM's valuation gap versus peers narrow longer term, driven by revenue and cost synergies in Stericycle and sustainability projects gaining traction. Top 5 Downgrades: Telsey Advisory downgraded Deckers Outdoor (DECK) to Market Perform from Outperform with a price target of $120, down from $240. The firm cites the deceleration of the HOKA and DTC businesses, margin pressures from channel mix shifts towards wholesale, the potential for increased promotions against low levels in the prior years, and tariff costs, along with general challenges to overall global macro visibility, for its downgrade. Evercore ISI and KeyBanc also downgraded Deckers Outdoor to Neutral-equivalent ratings. Erste Group downgraded McDonald's (MCD) to Hold from Buy. The company's sales will 'grow very slowly' in 2025 and a higher growth rate is 'only realistic in the coming year,' the firm tells investors in a research note. Raymond James downgraded Booz Allen (BAH) to Market Perform from Outperform with no price target following a 'weak' quarterly report and guidance. JPMorgan downgraded GFL Environmental (GFL) to Neutral from Overweight with a price target of $54, up from $51, following a transfer in analyst coverage. GFL's risk/reward is balanced at these levels, given the shares reflect the company's improved cash conversion profile, the firm says. Bernstein downgraded TechnipFMC (FTI) to Market Perform from Outperform with a price target of $32, down from $33. The firm's estimates for TechnipFMC in 2027 and 2028 are below consensus. Top 5 Initiations: Citi initiated coverage of US Foods (USFD) with a Buy rating and $95 price target. The firm views the North America food distributor industry backdrop favorably, saying restaurant wallet share is a likely 'buffer' to macro risks while the sector has limited tariff risk. Citi also started coverage of Performance Food Group (PFGC) with a Buy rating and Sysco (SYY) with a Neutral. Morgan Stanley resumed coverage of Loar Holdings (LOAR) with an Overweight rating and $100 price target. Loar continues to execute on its organic and inorganic growth strategy and end market demand remains robust with record bookings, the firm tells investors. Lucid Capital initiated coverage of Edesa Biotech (EDSA) with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. Texas Capital initiated coverage of Universal Technical (UTI) with a Buy rating and $38 price target. Universal embarked on re-energization of operational processes, real-estate rationalizations and cost-cutting about six years ago following years of sluggish student enrollment and started showing student-starts growth, a return to breakeven and 'decent profitability,' the firm tells investors. Texas Capital also started coverage of Lincoln Educational (LINC), Lindblad Expeditions (LIND), and American Public Education (APEI) with Buy ratings. Cantor Fitzgerald initiated coverage of Serve Robotics (SERV) with an Overweight rating and $17 price target. The firm believes the company benefits from 'compelling' unit economics, material partnerships for scale and expansion, and multiple applications that increase its total addressable market.
Yahoo
23-05-2025
- Business
- Yahoo
Deckers downgraded, Morgan Stanley upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The 5 Upgrades: Erste Group upgraded Morgan Stanley (MS) to Buy from Hold. The company's earnings in 2025 will increase more strongly than revenue and its return on equity is significantly higher than that competitors, the firm tells investors in a research note. Baird upgraded (WIX) to Outperform from Neutral with a price target of $190, down from $215. The company's product "is becoming increasingly compelling" and expectations now seem more reasonable post the Q1 report, the firm tells investors in a research note. Northland upgraded SolarEdge (SEDG) to Market Perform from Underperform with an unchanged price target of $15.50. Shares have declined meaningfully since the firm's downgrade on May 16, notes the firm, which argues that regardless of what legislation ultimately looks like, utility-scale solar is "the cheapest and fastest way to add generation capacity" and SolarEdge is well-positioned as a non-Chinese supplier with cybersecurity capabilities. Redburn Atlantic upgraded Charles River (CRL) to Buy from Neutral with a price target of $182, down from $188. The announcement that activist Elliott is now Charles River's largest investor and the company conducting a "wide-ranging" strategic offers a potential catalyst for the shares, the firm tells investors in a research note. JPMorgan upgraded WM (WM) to Overweight from Neutral with a price target of $277, up from $225, after transfer in analyst coverage. The firm expects WM's valuation gap versus peers narrow longer term, driven by revenue and cost synergies in Stericycle and sustainability projects gaining traction. Top 5 Downgrades: Telsey Advisory downgraded Deckers Outdoor (DECK) to Market Perform from Outperform with a price target of $120, down from $240. The firm cites the deceleration of the HOKA and DTC businesses, margin pressures from channel mix shifts towards wholesale, the potential for increased promotions against low levels in the prior years, and tariff costs, along with general challenges to overall global macro visibility, for its downgrade. Evercore ISI and KeyBanc also downgraded Deckers Outdoor to Neutral-equivalent ratings. Erste Group downgraded McDonald's (MCD) to Hold from Buy. The company's sales will "grow very slowly" in 2025 and a higher growth rate is "only realistic in the coming year," the firm tells investors in a research note. Raymond James downgraded Booz Allen (BAH) to Market Perform from Outperform with no price target following a "weak" quarterly report and guidance. JPMorgan downgraded GFL Environmental (GFL) to Neutral from Overweight with a price target of $54, up from $51, following a transfer in analyst coverage. GFL's risk/reward is balanced at these levels, given the shares reflect the company's improved cash conversion profile, the firm says. Bernstein downgraded TechnipFMC (FTI) to Market Perform from Outperform with a price target of $32, down from $33. The firm's estimates for TechnipFMC in 2027 and 2028 are below consensus. Top 5 Initiations: Citi initiated coverage of US Foods (USFD) with a Buy rating and $95 price target. The firm views the North America food distributor industry backdrop favorably, saying restaurant wallet share is a likely "buffer" to macro risks while the sector has limited tariff risk. Citi also started coverage of Performance Food Group (PFGC) with a Buy rating and Sysco (SYY) with a Neutral. Morgan Stanley resumed coverage of Loar Holdings (LOAR) with an Overweight rating and $100 price target. Loar continues to execute on its organic and inorganic growth strategy and end market demand remains robust with record bookings, the firm tells investors. Lucid Capital initiated coverage of Edesa Biotech (EDSA) with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. Texas Capital initiated coverage of Universal Technical (UTI) with a Buy rating and $38 price target. Universal embarked on re-energization of operational processes, real-estate rationalizations and cost-cutting about six years ago following years of sluggish student enrollment and started showing student-starts growth, a return to breakeven and "decent profitability," the firm tells investors. Texas Capital also started coverage of Lincoln Educational (LINC), Lindblad Expeditions (LIND), and American Public Education (APEI) with Buy ratings. Cantor Fitzgerald initiated coverage of Serve Robotics (SERV) with an Overweight rating and $17 price target. The firm believes the company benefits from "compelling" unit economics, material partnerships for scale and expansion, and multiple applications that increase its total addressable market.
